clioquinol has been researched along with Alzheimer Disease in 105 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cholinesterase inhibitors and memantine are widely used for the treatment of Alzheimer disease (AD) and other non-AD dementia worldwide." | 4.86 | [Drug therapy for Alzheimer's disease]. ( Shoji, M, 2010) |
| "Alzheimer's disease is the most frequent neurodegenerative illness in the long run." | 3.01 | Understanding Alzheimer's Disease and its Metal Chelation Therapeutics: A Narrative Review. ( Karwasra, R; Thakur, R; Umar, T, 2023) |
| "PBT2 is a metal-protein attenuating compound (MPAC) that affects the Cu2(+)-mediated and Zn2(+)-mediated toxic oligomerisation of Abeta seen in Alzheimer's disease (AD)." | 2.73 | Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. ( Ames, D; Batsman, S; Blennow, K; Bush, AI; Harrison, J; Lannfelt, L; Masters, CL; Murdoch, R; Ritchie, CW; Targum, S; Wilson, J; Zetterberg, H, 2008) |
| "Alzheimer's disease is the most common form of dementia in the elderly, and it is characterized by elevated brain iron levels and accumulation of copper and zinc in cerebral beta-amyloid deposits (e." | 2.44 | Therapeutics for Alzheimer's disease based on the metal hypothesis. ( Bush, AI; Tanzi, RE, 2008) |
| " We also describe how the development of therapeutic agents designed to modulate metal bioavailability has provided promising results in the treatment of Alzheimer's disease." | 2.43 | Therapeutic treatments for Alzheimer's disease based on metal bioavailability. ( Barnham, KJ; Bush, AI; Crouch, PJ; White, AR, 2006) |
| "The cause of Alzheimer's disease (AD) is closely related to the aggregation of a normal protein, beta-amyloid (Abeta), within the neocortex." | 2.42 | The metallobiology of Alzheimer's disease. ( Bush, AI, 2003) |
| "Clioquinol is an example from this class, which has recently shown encouraging efficacy from early clinical evaluation in the absence of any compelling evidence of subacute myelopathic optic neuritis, which has been associated with this drug's use in Japanese populations." | 2.42 | Metal-protein attenuating compounds and Alzheimer's disease. ( Bush, AI; Masters, CL; Ritchie, CW, 2004) |
| "Clioquinol is a drug that acts on amyloid by perturbing amyloid's metallo-chemistry, and Clioquinol treatment has been shown to be beneficial in a mouse model of AD." | 2.41 | '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. ( Melov, S, 2002) |
| "Although Alzheimer's disease (AD) was first described over a century ago, it remains the leading cause of age-related dementia." | 1.72 | Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs. ( Dolgova, NV; George, GN; Harris, HH; Kroll, T; Millhauser, GL; Pickering, IJ; Pushie, MJ; Roseman, G; Schilling, KM; Sokaras, D; Summers, KL, 2022) |
| "To target the multi-facets of Alzheimer's disease (AD), a series of novel GSK-3β inhibitors containing the 2,3-diaminopyridine moiety were designed and synthesized." | 1.51 | Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease. ( Liu, P; Liu, ZP; Shi, XL; Wu, JD, 2019) |
| " Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14." | 1.48 | Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018) |
| " Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described." | 1.42 | Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases. ( Kador, PF; Kawada, H, 2015) |
| "Patients of Alzheimer's disease (AD) frequently have lower bone mineral density and higher rate of hip fracture." | 1.42 | Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease. ( Cui, S; Guo, JP; Pan, JX; Xia, WF; Xiong, L; Xiong, WC, 2015) |
| " The pathogenic Aβ 1-42 peptide forms more oligomers and is more toxic than Aβ 1-40 and genome-wide genetic screens identified genes that are known risk factors for AD." | 1.40 | Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. ( Caldwell, GA; Caldwell, KA; Hamamichi, S; Lindquist, S; Matlack, KE; Narayan, P; Tardiff, DF, 2014) |
| " elegans model of full length Aß₁₋₄₂ expression can now be adopted for use in screens to rapidly identify and assist in development of potential therapeutics and to study underlying toxic mechanism(s) of Aß." | 1.38 | Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. ( Barnham, KJ; Bush, AI; Cherny, RA; Kenche, VB; Link, CD; Masters, CL; McColl, G; Pukala, TL; Roberts, BR; Roberts, CM; Ryan, TM, 2012) |
| " However, clinical trial studies have shown that long-term use of metal chelator can cause adverse side effect, subacute myelo-optic neuropathy." | 1.38 | Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer's disease treatment. ( Chen, C; Geng, J; Li, M; Qu, X; Wu, L, 2012) |
| "As a disease-modifying approach for Alzheimer's disease (AD), clioquinol (CQ) targets beta-amyloid (Abeta) reactions with synaptic Zn and Cu yet promotes metal uptake." | 1.35 | Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. ( Adlard, PA; Barnham, KJ; Bush, AI; Cappai, R; Charman, SA; Cherny, RA; Cortes, M; Deleva, K; Finkelstein, DI; Gautier, E; Kok, G; Laughton, K; Li, QX; Liu, X; Lynch, T; Masters, CL; Nicolazzo, JA; Perez, K; Ritchie, CW; Robb, E; Smith, JP; Tanzi, RE; Volitakis, I; Wilkins, S, 2008) |
| "Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity." | 1.35 | Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. ( Casamenti, F; Casini, A; Fiorentini, A; Francese, S; Gabbiani, C; Grossi, C; Luccarini, I; Messori, L; Moneti, G; Rosi, MC, 2009) |
| "Isoflurane also promotes Abeta aggregation." | 1.34 | The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. ( Crosby, G; Culley, DJ; Dong, Y; Maeda, U; Moir, RD; Tanzi, RE; Xia, W; Xie, Z, 2007) |
| "The key protein in Alzheimer's disease, the amyloid precursor protein (APP), is a ubiquitously expressed copper-binding glycoprotein that gives rise to the Abeta amyloid peptide." | 1.32 | Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. ( Bayer, TA; Cappai, R; Hafner, M; Multhaup, G; Simons, A; Strauss, M; Treiber, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 47 (44.76) | 29.6817 |
| 2010's | 46 (43.81) | 24.3611 |
| 2020's | 12 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Moret, V | 1 |
| Laras, Y | 1 |
| Pietrancosta, N | 1 |
| Garino, C | 1 |
| Quéléver, G | 1 |
| Rolland, A | 1 |
| Mallet, B | 1 |
| Norreel, JC | 1 |
| Kraus, JL | 1 |
| Chen, SY | 1 |
| Chen, Y | 1 |
| Li, YP | 1 |
| Chen, SH | 1 |
| Tan, JH | 1 |
| Ou, TM | 1 |
| Gu, LQ | 1 |
| Huang, ZS | 1 |
| Bulic, B | 1 |
| Pickhardt, M | 1 |
| Mandelkow, E | 1 |
| Lu, C | 1 |
| Guo, Y | 1 |
| Yan, J | 3 |
| Luo, Z | 2 |
| Luo, HB | 2 |
| Yan, M | 1 |
| Huang, L | 8 |
| Li, X | 10 |
| Li, SY | 1 |
| Wang, XB | 3 |
| Kong, LY | 3 |
| Kawada, H | 1 |
| Kador, PF | 1 |
| Wang, Z | 6 |
| Wang, Y | 3 |
| Wang, B | 2 |
| Li, W | 3 |
| Martínez, A | 1 |
| Alcendor, R | 1 |
| Rahman, T | 1 |
| Podgorny, M | 1 |
| Sanogo, I | 1 |
| McCurdy, R | 1 |
| Wang, ZM | 1 |
| Cai, P | 2 |
| Liu, QH | 2 |
| Xu, DQ | 1 |
| Yang, XL | 2 |
| Wu, JJ | 2 |
| Wang, H | 2 |
| Lu, Z | 1 |
| Zheng, X | 2 |
| Ni, W | 1 |
| Zhu, J | 2 |
| Fu, Y | 1 |
| Lian, F | 1 |
| Zhang, N | 1 |
| Li, J | 3 |
| Zhang, H | 1 |
| Mao, F | 4 |
| Chen, H | 1 |
| Lu, CJ | 1 |
| Li, F | 1 |
| Wang, J | 1 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 1 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhang, HY | 1 |
| Hu, J | 2 |
| Yang, X | 2 |
| Feng, X | 2 |
| Chan, ASC | 1 |
| D'Acunto, CW | 1 |
| Kaplánek, R | 1 |
| Gbelcová, H | 1 |
| Kejík, Z | 1 |
| Bříza, T | 1 |
| Vasina, L | 1 |
| Havlík, M | 1 |
| Ruml, T | 1 |
| Král, V | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Shi, XL | 1 |
| Wu, JD | 2 |
| Liu, P | 1 |
| Liu, ZP | 2 |
| Yang, Z | 1 |
| Song, Q | 1 |
| Cao, Z | 1 |
| Yu, G | 1 |
| Liu, Z | 2 |
| Tan, Z | 1 |
| Deng, Y | 1 |
| Nerella, A | 1 |
| Jeripothula, M | 1 |
| Bowroju, SK | 1 |
| Penthala, NR | 1 |
| Lakkaniga, NR | 1 |
| Balasubramaniam, M | 1 |
| Ayyadevara, S | 1 |
| Shmookler Reis, RJ | 1 |
| Crooks, PA | 1 |
| Wang, XX | 1 |
| Xie, F | 1 |
| Jia, CC | 1 |
| Yan, N | 1 |
| Zeng, YL | 1 |
| Cotrina, EY | 1 |
| Santos, LM | 1 |
| Rivas, J | 1 |
| Blasi, D | 1 |
| Leite, JP | 1 |
| Liz, MA | 1 |
| Busquets, MA | 1 |
| Planas, A | 1 |
| Prohens, R | 1 |
| Gimeno, A | 1 |
| Jiménez-Barbero, J | 1 |
| Gales, L | 1 |
| Llop, J | 1 |
| Quintana, J | 1 |
| Cardoso, I | 1 |
| Arsequell, G | 1 |
| Lin, G | 1 |
| Zhu, F | 1 |
| Kanaan, NM | 1 |
| Asano, R | 1 |
| Shirafuji, N | 1 |
| Sasaki, H | 1 |
| Yamaguchi, T | 1 |
| Enomoto, S | 1 |
| Endo, Y | 1 |
| Ueno, A | 1 |
| Ikawa, M | 1 |
| Hayashi, K | 1 |
| Yamamura, O | 1 |
| Yen, SH | 1 |
| Nakamoto, Y | 1 |
| Hamano, T | 1 |
| Summers, KL | 3 |
| Roseman, G | 1 |
| Schilling, KM | 1 |
| Dolgova, NV | 1 |
| Pushie, MJ | 2 |
| Sokaras, D | 1 |
| Kroll, T | 1 |
| Harris, HH | 2 |
| Millhauser, GL | 2 |
| Pickering, IJ | 3 |
| George, GN | 3 |
| Thakur, R | 1 |
| Karwasra, R | 1 |
| Umar, T | 1 |
| Cao, M | 1 |
| Xiang, H | 1 |
| Wang, W | 1 |
| Pretsch, D | 1 |
| Rollinger, JM | 1 |
| Schmid, A | 1 |
| Genov, M | 1 |
| Wöhrer, T | 1 |
| Krenn, L | 1 |
| Moloney, M | 1 |
| Kasture, A | 1 |
| Hummel, T | 1 |
| Pretsch, A | 1 |
| Lu, L | 1 |
| Wang, S | 1 |
| Tang, C | 1 |
| Zhang, Y | 1 |
| Yao, G | 1 |
| Zeng, J | 1 |
| Ge, S | 1 |
| Wen, H | 1 |
| Xu, M | 1 |
| Guyatt, G | 1 |
| Xu, N | 1 |
| Roseman, GP | 1 |
| Sopasis, GJ | 1 |
| Cilliers, K | 1 |
| Rajasekhar, K | 1 |
| Mehta, K | 1 |
| Govindaraju, T | 1 |
| Saini, RK | 1 |
| Shuaib, S | 1 |
| Goyal, D | 1 |
| Goyal, B | 1 |
| Zhang, YH | 1 |
| Raymick, J | 1 |
| Sarkar, S | 1 |
| Lahiri, DK | 2 |
| Ray, B | 1 |
| Holtzman, D | 1 |
| Dumas, M | 1 |
| Schmued, LC | 1 |
| Nienaber, KH | 1 |
| Cotelesage, JJ | 1 |
| Ponomarenko, O | 1 |
| Nichol, HK | 1 |
| Sampson, EL | 2 |
| Jenagaratnam, L | 4 |
| McShane, R | 4 |
| Matlack, KE | 1 |
| Tardiff, DF | 1 |
| Narayan, P | 1 |
| Hamamichi, S | 1 |
| Caldwell, KA | 1 |
| Caldwell, GA | 1 |
| Lindquist, S | 1 |
| Jia, X | 1 |
| Miao, H | 1 |
| Sun, Y | 3 |
| Ryan, TM | 2 |
| Roberts, BR | 2 |
| McColl, G | 2 |
| Hare, DJ | 1 |
| Doble, PA | 1 |
| Li, QX | 4 |
| Lind, M | 1 |
| Roberts, AM | 1 |
| Mertens, HD | 1 |
| Kirby, N | 1 |
| Pham, CL | 1 |
| Hinds, MG | 1 |
| Adlard, PA | 4 |
| Barnham, KJ | 11 |
| Curtain, CC | 1 |
| Masters, CL | 11 |
| Seo, BR | 1 |
| Lee, SJ | 1 |
| Cho, KS | 1 |
| Yoon, YH | 1 |
| Koh, JY | 1 |
| Wu, R | 1 |
| Guo, JP | 1 |
| Pan, JX | 1 |
| Xiong, L | 1 |
| Xia, WF | 1 |
| Cui, S | 1 |
| Xiong, WC | 1 |
| Prati, F | 1 |
| Bergamini, C | 1 |
| Fato, R | 1 |
| Soukup, O | 1 |
| Korabecny, J | 1 |
| Andrisano, V | 1 |
| Bartolini, M | 1 |
| Bolognesi, ML | 1 |
| Su, T | 1 |
| Zhang, T | 1 |
| Xie, S | 1 |
| Wu, Y | 1 |
| Saito, Y | 1 |
| Sakai, K | 1 |
| Konagaya, M | 1 |
| Cherny, RA | 7 |
| Finkelstein, DI | 2 |
| Gautier, E | 1 |
| Robb, E | 1 |
| Cortes, M | 1 |
| Volitakis, I | 6 |
| Liu, X | 1 |
| Smith, JP | 1 |
| Perez, K | 1 |
| Laughton, K | 1 |
| Charman, SA | 1 |
| Nicolazzo, JA | 1 |
| Wilkins, S | 1 |
| Deleva, K | 1 |
| Lynch, T | 1 |
| Kok, G | 1 |
| Ritchie, CW | 6 |
| Tanzi, RE | 7 |
| Cappai, R | 4 |
| Bush, AI | 17 |
| Relkin, NR | 1 |
| Lannfelt, L | 2 |
| Blennow, K | 2 |
| Zetterberg, H | 2 |
| Batsman, S | 1 |
| Ames, D | 2 |
| Harrison, J | 2 |
| Targum, S | 1 |
| Murdoch, R | 1 |
| Wilson, J | 1 |
| Bolognin, S | 2 |
| Zatta, P | 3 |
| Drago, D | 2 |
| Tognon, G | 1 |
| Parnigotto, PP | 1 |
| Ricchelli, F | 1 |
| Cahoon, L | 1 |
| Grossi, C | 1 |
| Francese, S | 1 |
| Casini, A | 1 |
| Rosi, MC | 1 |
| Luccarini, I | 1 |
| Fiorentini, A | 1 |
| Gabbiani, C | 1 |
| Messori, L | 2 |
| Moneti, G | 1 |
| Casamenti, F | 1 |
| Rival, T | 1 |
| Page, RM | 1 |
| Chandraratna, DS | 1 |
| Sendall, TJ | 1 |
| Ryder, E | 1 |
| Liu, B | 1 |
| Lewis, H | 1 |
| Rosahl, T | 1 |
| Hider, R | 1 |
| Camargo, LM | 1 |
| Shearman, MS | 1 |
| Crowther, DC | 1 |
| Lomas, DA | 1 |
| Sensi, SL | 1 |
| Mancino, AM | 1 |
| Hindo, SS | 1 |
| Kochi, A | 1 |
| Lim, MH | 1 |
| Faux, NG | 1 |
| Gunn, A | 1 |
| Rembach, A | 1 |
| Tsatsanis, A | 1 |
| Bedo, J | 1 |
| Ingelsson, M | 1 |
| Cummings, JL | 1 |
| Herd, CM | 1 |
| Shoji, M | 1 |
| Budimir, A | 1 |
| Humbert, N | 1 |
| Elhabiri, M | 1 |
| Osinska, I | 1 |
| Biruš, M | 1 |
| Albrecht-Gary, AM | 1 |
| Barcia, E | 1 |
| Salama, A | 1 |
| Fernández-Carballido, A | 1 |
| Negro, S | 1 |
| Kenche, VB | 2 |
| Bica, L | 1 |
| White, AR | 5 |
| Nurjono, M | 1 |
| Filiz, G | 2 |
| Crouch, PJ | 4 |
| Donnelly, PS | 2 |
| Savva, MS | 1 |
| Hung, LW | 2 |
| Mot, AI | 1 |
| Parker, SJ | 1 |
| Greenough, MA | 1 |
| Faller, P | 1 |
| Wang, T | 1 |
| Wang, CY | 1 |
| Shan, ZY | 1 |
| Teng, WP | 1 |
| Wang, ZY | 1 |
| Pukala, TL | 1 |
| Roberts, CM | 1 |
| Link, CD | 1 |
| Geng, J | 1 |
| Li, M | 1 |
| Wu, L | 1 |
| Chen, C | 1 |
| Qu, X | 1 |
| Helmuth, L | 2 |
| Rogers, JT | 1 |
| Randall, JD | 1 |
| Cahill, CM | 1 |
| Eder, PS | 1 |
| Huang, X | 2 |
| Gunshin, H | 1 |
| Leiter, L | 1 |
| McPhee, J | 1 |
| Sarang, SS | 1 |
| Utsuki, T | 1 |
| Greig, NH | 1 |
| Giordano, T | 1 |
| Gullans, SR | 1 |
| Cole, GM | 1 |
| Abramov, AY | 1 |
| Canevari, L | 1 |
| Duchen, MR | 1 |
| Finefrock, AE | 1 |
| Doraiswamy, PM | 2 |
| Mastwyk, M | 2 |
| Macfarlane, S | 2 |
| LoGiudice, D | 1 |
| Sullivan, KA | 1 |
| Rosenberg, RN | 2 |
| Mackinnon, A | 1 |
| MacGregor, L | 1 |
| Kiers, L | 1 |
| Cherny, R | 1 |
| Tammer, A | 1 |
| Carrington, D | 1 |
| Mavros, C | 1 |
| Xilinas, M | 1 |
| Davis, S | 1 |
| Beyreuther, K | 2 |
| Di Vaira, M | 1 |
| Bazzicalupi, C | 1 |
| Orioli, P | 1 |
| Bruni, B | 1 |
| Treiber, C | 1 |
| Simons, A | 1 |
| Strauss, M | 1 |
| Hafner, M | 1 |
| Bayer, TA | 2 |
| Multhaup, G | 2 |
| McCarthy, AM | 1 |
| Huckle, R | 1 |
| Raman, B | 1 |
| Ban, T | 1 |
| Yamaguchi, K | 1 |
| Sakai, M | 1 |
| Kawai, T | 1 |
| Naiki, H | 1 |
| Goto, Y | 1 |
| Ibach, B | 1 |
| Haen, E | 1 |
| Marienhagen, J | 1 |
| Hajak, G | 1 |
| Puglielli, L | 1 |
| Friedlich, AL | 1 |
| Setchell, KD | 1 |
| Nagano, S | 1 |
| Opazo, C | 2 |
| Wade, JD | 1 |
| Melov, S | 2 |
| Kovacs, DM | 1 |
| Xiong, GL | 1 |
| Luza, S | 1 |
| Villemagne, VL | 1 |
| Rowe, C | 1 |
| Strozyk, D | 1 |
| Masters, C | 1 |
| Du, T | 2 |
| Laughton, KM | 1 |
| Sharples, RA | 1 |
| Xilinas, ME | 2 |
| Hoke, DE | 1 |
| Holsinger, RM | 1 |
| Evin, G | 1 |
| Hill, AF | 1 |
| Domingo, JL | 1 |
| Schäfer, S | 1 |
| Pajonk, FG | 1 |
| Xie, Z | 1 |
| Dong, Y | 1 |
| Maeda, U | 1 |
| Moir, RD | 2 |
| Xia, W | 1 |
| Culley, DJ | 1 |
| Crosby, G | 1 |
| Ferrada, E | 1 |
| Arancibia, V | 1 |
| Loeb, B | 1 |
| Norambuena, E | 1 |
| Olea-Azar, C | 1 |
| Huidobro-Toro, JP | 1 |
| Sampson, E | 1 |
| Price, KA | 1 |
| Caragounis, A | 1 |
| Iwata, N | 1 |
| Tabira, T | 1 |
| Gouras, GK | 1 |
| Beal, MF | 1 |
| Atwood, CS | 1 |
| Gray, DN | 1 |
| Jones, WD | 1 |
| McLean, CA | 1 |
| Fraser, FW | 1 |
| Kim, Y | 1 |
| Goldstein, LE | 1 |
| Lim, JT | 1 |
| Zheng, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease[NCT00471211] | Phase 2 | 80 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease[NCT01590888] | Phase 2 | 109 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PBT2 250mg | -2.3 |
| PBT2 100mg | 3.0 |
| Sugar Pill | 0.7 |
Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | ratio (Mean) |
|---|---|
| PBT2 250mg | 1.97 |
| PBT2 100mg | 0.14 |
| Sugar Pill | -1.72 |
Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | mg/mL (Mean) |
|---|---|
| PBT2 250mg | -3.18 |
| PBT2 100mg | -2.09 |
| Sugar Pill | -3.07 |
Biomarkers assessed primarily with plasma selenium as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | ug/L (Mean) |
|---|---|
| PBT2 250mg | 1.3 |
| PBT2 100mg | -6.3 |
| Sugar Pill | 2.0 |
Measure of the structural brain volume as assessed by the left caudate volume. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | mm^3 (Mean) |
|---|---|
| PBT2 250mg | 50.0 |
| PBT2 100mg | 27.5 |
| Sugar Pill | -170.5 |
Measure of whole brain iron concentrations. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | mm^3 (Mean) |
|---|---|
| PBT2 250mg | 0.0029 |
| PBT2 100mg | 0.0067 |
| Sugar Pill | 0.0098 |
"Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).~The Trails Making Test Part B actual change from baseline at Week 26 was analysed." (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | seconds (Mean) |
|---|---|
| PBT2 250mg | -6.3 |
| PBT2 100mg | 12.8 |
| Sugar Pill | 8.9 |
"Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.~Higher scores on the function scales indicate better functioning than lower scores." (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PBT2 250mg | 1.1 |
| PBT2 100mg | 1.3 |
| Sugar Pill | 1.3 |
Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values >1. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | ratio (Mean) |
|---|---|
| PBT2 250mg | 1.313 |
| PBT2 100mg | 1.276 |
| Sugar Pill | 1.176 |
Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60). (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PBT2 250mg | -0.7 |
| PBT2 100mg | 1.3 |
| Sugar Pill | -1.3 |
Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| PBT2 250mg | -0.4258 |
| PBT2 100mg | 0.0832 |
| Sugar Pill | 35.5302 |
As measured by the total number of participants in each dose group who reported at least one adverse events during the study, (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | participants (Number) |
|---|---|
| PBT2 250mg | 32 |
| PBT2 100mg | 30 |
| Sugar Pill | 28 |
Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement. (NCT01590888)
Timeframe: Baseline to 26 weeks
| Intervention | z score (Mean) | ||
|---|---|---|---|
| Main Composite z-score | Exploratory Composite z-score | Executive Function z-score | |
| PBT2 100mg | -0.0413 | -0.0287 | -0.1026 |
| PBT2 250mg | 0.0592 | 0.0530 | 0.2274 |
| Sugar Pill | -0.0194 | -0.0144 | 0.0553 |
25 reviews available for clioquinol and Alzheimer Disease
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; P | 2013 |
Understanding Alzheimer's Disease and its Metal Chelation Therapeutics: A Narrative Review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Humans; Metals | 2023 |
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anx | 2020 |
Trace element alterations in Alzheimer's disease: A review.
Topics: Alzheimer Disease; Clioquinol; Copper; Deferoxamine; Humans; Metals; Penicillamine; Siderophores; Tr | 2021 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Humans; Randomized Con | 2014 |
Therapeutics for Alzheimer's disease based on the metal hypothesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clioquinol; Humans; Metalloproteins; Metals; Mode | 2008 |
Alzheimer's disease, metal ions and metal homeostatic therapy.
Topics: Alzheimer Disease; Animals; Clioquinol; Homeostasis; Humans; Metals; Plaque, Amyloid | 2009 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase In | 2010 |
Alzheimer's disease & metals: therapeutic opportunities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Cations; Clinical Trials as Topic; | 2011 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2012 |
Modulating metals as a therapeutic strategy for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clioquinol; Copper; Humans; Metals; Molecular Tar | 2012 |
The metallobiology of Alzheimer's disease.
Topics: Alzheimer Disease; Amebicides; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Clioq | 2003 |
Current status of metals as therapeutic targets in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Copper; Deferoxamin | 2003 |
Metal-protein attenuating compounds and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clioquinol; Humans; Mice | 2004 |
PBT-1 Prana Biotechnology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clinical Trials as Topic; Clioquinol; Humans | 2005 |
Translational research on the way to effective therapy for Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Apolipoprot | 2005 |
Pharmacological strategies for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Clioquinol; Drug Delivery Systems; Humans; Pharmaceutical Preparations | 2006 |
Clioquinol for the treatment of Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2006 |
Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents.
Topics: Aluminum; Alzheimer Disease; Chelating Agents; Clioquinol; Copper; Humans; Mercury; Zinc | 2006 |
Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Biological Availability; Brain; Clioquinol | 2006 |
Metal protein attenuating compounds for the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2008 |
The role of metals in modulating metalloprotease activity in the AD brain.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Brain; Cell Culture Techniques; Chelatin | 2008 |
[Therapeutic effect of clioquinol for Alzheimer disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthetics, Inhalation; Animals; Brain; Caspase 3; Choles | 2008 |
Metal chelator decreases Alzheimer beta-amyloid plaques.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Plaque, Amyloid | 2001 |
'...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Disease Models, Ani | 2002 |
4 trials available for clioquinol and Alzheimer Disease
| Article | Year |
|---|---|
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Do | 2008 |
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Do | 2008 |
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Do | 2008 |
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Do | 2008 |
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Area Under Curve; Australia; Clioquinol; Cognition Disorde | 2010 |
Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Caregivers; Clioquinol; Consumer Behavior; Co | 2003 |
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Cog | 2003 |
76 other studies available for clioquinol and Alzheimer Disease
| Article | Year |
|---|---|
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Copper; Heterocyclic Compounds, 1-Ring; Mo | 2006 |
Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line, Tumor; Chelating Agents; Curcumin | 2011 |
Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cholinesterase | 2013 |
Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line, Tumor; Copper; Humans; Neuroprote | 2014 |
Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Biological Availability; Brain; Cell Line, Tumor; Cell Sur | 2015 |
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; | 2015 |
Ionophoric polyphenols selectively bind Cu(2+), display potent antioxidant and anti-amyloidogenic properties, and are non-toxic toward Tetrahymena thermophila.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Carbon-13 Magnetic Reso | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2016 |
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line; Ch | 2016 |
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Copper; Drug Design; Hu | 2016 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Bra | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des | 2018 |
Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cations; Cell Proliferation; Cell Survival; Chelating Agen | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amines; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Chelating | 2019 |
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Drug Discovery; Flurbiprofen; Humans; Ligands; | 2020 |
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cata | 2021 |
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzylamines; Bu | 2021 |
Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Survival; Copper; Dose-Response Relationship, Drug; H | 2021 |
Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
Topics: Alzheimer Disease; Calorimetry; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Mo | 2021 |
Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein.
Topics: Alzheimer Disease; Autophagy; Cell Line, Tumor; Clioquinol; Copper; Gene Expression Regulation; Huma | 2021 |
Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Humans; Ions; Metals | 2022 |
WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthetics, General; Animals; Benzofurans; Biological Ava | 2019 |
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modi | 2020 |
Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Coordination Complexes; Copper; Density Fu | 2020 |
Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage.
Topics: Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Clioquinol; Mitochondria; Oxidative Stre | 2018 |
Insights into the inhibitory mechanism of a resveratrol and clioquinol hybrid against Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Humans; Hydrogen Bonding; Hydrophobic and Hydr | 2019 |
Can we reverse Alzheimer's? New approaches from Harvard offer hope.
Topics: Alzheimer Disease; Clioquinol; Cognition; Health Behavior; Humans; Mental Processes; Risk Reduction | 2013 |
Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Ant | 2013 |
The solution structure of the copper clioquinol complex.
Topics: Alzheimer Disease; Chelating Agents; Clioquinol; Copper; Humans; Molecular Structure; Neoplasms; Sol | 2014 |
Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caenorhabditis elegans; Clioquinol; Drug Discover | 2014 |
New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol.
Topics: Absorption, Physiological; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Br | 2014 |
Design, synthesis, and evaluation of multitarget-directed selenium-containing clioquinol derivatives for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Capillary Perm | 2014 |
Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzothiazoles; Biophysics; Caenorhabditis elegan | 2015 |
The zinc ionophore clioquinol reverses autophagy arrest in chloroquine-treated ARPE-19 cells and in APP/mutant presenilin-1-transfected Chinese hamster ovary cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Chloro | 2015 |
Computer-assisted designed "selenoxy-chinolin": a new catalytic mechanism of the GPx-like cycle and inhibition of metal-free and metal-associated Aβ aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Azoles; Biocompatible Materials; Bl | 2015 |
Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Bone Resorption; Cation Transport Proteins; Cell Differentiation; Cells, | 2015 |
Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; | 2016 |
Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; | 2016 |
The prevalence of dementia in subacute myelo-optico-neuropathy (SMON) patients who underwent medical checkups.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Infective Agents; Clioquinol; Dementia; Female; Hum | 2016 |
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2008 |
Testing the mettle of PBT2 for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Clinical Trials, Phase II as Topic; Clioquinol; Huma | 2008 |
Mutual stimulation of beta-amyloid fibrillogenesis by clioquinol and divalent metals.
Topics: Alzheimer Disease; Amino Acid Substitution; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Chelat | 2008 |
The curious case of clioquinol.
Topics: Alzheimer Disease; Anti-Infective Agents, Local; Blindness; Clioquinol; Humans; Japan; Memory; Memor | 2009 |
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2009 |
Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Apoferritins; Brai | 2009 |
Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Humans; Metals; Solu | 2009 |
Hydroxyquinoline based binders: promising ligands for chelatotherapy?
Topics: Alzheimer Disease; Cations, Divalent; Chelating Agents; Clioquinol; Colorimetry; Drug Stability; Hum | 2011 |
Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer's disease.
Topics: Alzheimer Disease; Biocompatible Materials; Cell Culture Techniques; Cell Death; Cell Line, Tumor; C | 2011 |
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Clioquinol; Dendritic Spines; Disease Models, Animal; F | 2011 |
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blotting, Western; Calcineurin; Calcineurin Inhibitors; Ca | 2011 |
Copper in Alzheimer disease: too much, too little, or misplaced?
Topics: Alzheimer Disease; Animals; Brain; Clioquinol; Copper; Hepatolenticular Degeneration; Humans; Menkes | 2012 |
Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Chelating | 2012 |
Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis ele | 2012 |
Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Animals; Cell Survival; Clioquinol; Delayed-Action Preparations; Hydrogen Peroxid | 2012 |
New therapies. New Alzheimer's treatments that may ease the mind.
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2002 |
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.
Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Base Sequence; | 2002 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Astrocytes; Calcium; Calcium Signaling; | 2003 |
Metal chelation therapy for Alzheimer disease.
Topics: Alzheimer Disease; Chelating Agents; Chelation Therapy; Clioquinol; Humans; Zinc | 2003 |
Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
Topics: Alzheimer Disease; Brain; Chelating Agents; Clioquinol; Copper; Crystallography, X-Ray; Molecular Co | 2004 |
Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biological Transport, Active; Chelating | 2004 |
Prana Biotechnology, Limited: metal attenuation in the treatment of neurodegenerative disease.
Topics: Alzheimer Disease; Animals; Biotechnology; Clioquinol; Copper; Metalloproteins; Mice; Neurodegenerat | 2004 |
Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Infective Agents, Local; Circular Dichroism; Clioquin | 2005 |
Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Chelating Agents; Clioquinol; Cognition; Female; Hu | 2005 |
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cells, Cul | 2005 |
Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Clioquinol; Humans; Iodine Rad | 2006 |
Clioquinol treatment in familiar early onset of Alzheimer's disease: Ibach B et al., Pharmacopsychiatry 2005; 38: 178-179.
Topics: Alzheimer Disease; Anti-Infective Agents, Local; Clioquinol; Humans | 2006 |
Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Infective Agents, Local; Cell Line, Tumor; C | 2006 |
Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Animals, Genetica | 2007 |
The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anesthetics, Inhalat | 2007 |
Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy.
Topics: Adenosine Triphosphate; Algorithms; Alzheimer Disease; Animals; Chemical Phenomena; Chemistry, Physi | 2007 |
Neuroscience. An antibiotic to treat Alzheimer's?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Clinical Trials, Phase II as Topic; Clioqu | 2000 |
Clioquinol's return: cautions from Japan.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Clioquinol; Humans; Japan; Mice; Mye | 2001 |
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Copper | 2001 |